Compare MXL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | IMNM |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2009 | 2020 |
| Metric | MXL | IMNM |
|---|---|---|
| Price | $93.87 | $22.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $41.67 | $32.80 |
| AVG Volume (30 Days) | ★ 4.9M | 900.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.08 | ★ 51.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $478,596,000.00 | $6,941,000.00 |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $10.70 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.26 | $7.96 |
| 52 Week High | $106.28 | $27.65 |
| Indicator | MXL | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 49.13 |
| Support Level | $15.36 | $19.28 |
| Resistance Level | $104.27 | $23.25 |
| Average True Range (ATR) | 11.84 | 1.22 |
| MACD | -2.00 | 0.05 |
| Stochastic Oscillator | 52.17 | 56.39 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.